Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus
December 03, 2024 08:30 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus
Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group
November 21, 2024 05:30 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group
Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform
November 12, 2024 05:30 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split
November 01, 2024 16:30 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split
Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference
October 29, 2024 08:30 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference
Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform
October 15, 2024 05:00 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform
Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit
October 09, 2024 10:47 ET
|
Lipella Pharmaceuticals Inc.
PITTSBURGH, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious diseases...
Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus
September 24, 2024 08:00 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus
Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
August 27, 2024 08:00 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research
August 22, 2024 05:00 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research